Addex Therapeutics (FRA:APE1) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)


FRA:APE1 Addex Therapeutics Ltd FRA:APE1
7 GF Score
Price €4.90
GF Value €1.15
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics LT-Debt-to-Total-Asset?

Addex Therapeutics FRA:APE1 -2.97% 7 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates FRA:APE1 with a GF Score™ of 7/100 and a GF Value™ of €1.15. The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Addex Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

Addex Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.01). It may suggest that Addex Therapeutics is progressively becoming more dependent on debt to grow their business.

Addex Therapeutics  (FRA:APE1) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Addex Therapeutics LT-Debt-to-Total-Asset Related Terms

Addex Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics LT-Debt-to-Total-Asset Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.02 0.00 0.00

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.01
FRA:APE1
7GF Score
Addex Therapeutics Ltd FRA:APE1
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Addex Therapeutics LT-Debt-to-Total-Asset Calculation

Addex Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.029/6.82
=0.00

Addex Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0.027/5.229
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Addex Therapeutics (FRA:APE1) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Addex Therapeutics and its competitors.
Is Addex Therapeutics' LT-Debt-to-Total-Asset too high?
Addex Therapeutics' current LT-Debt-to-Total-Asset is 0.01. Overall, Addex Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Addex Therapeutics' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE1) has a current LT-Debt-to-Total-Asset of 0.01. The stock's GF Value™ is €1.15, compared to a current price of €4.90 — trading 326.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. Addex Therapeutics' overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE1), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?

Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued. The current stock price of €4.90 is trading 326.1% above its estimated GF Value™ of €1.15.

Key valuation signals for FRA:APE1:

  • LT-Debt-to-Total-Asset: 0.01
  • GF Value™: €1.15 vs. price of €4.90 (326.1% above fair value)
  • GF Score™: 7/100 with 6 warning signs

No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score

Get the complete analysis for FRA:APE1

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.90
Price
€1.15
GF Value